

# Joshua D. McCann, Pharm.D.

ASSOCIATE

Kansas City, MO | 816.360.4289  
[jmccann@polsinelli.com](mailto:jmccann@polsinelli.com)



Joshua McCann is committed to working with health care clients to achieve efficient and innovative outcomes for their immediate and long-term goals. He applies his understanding of health care issues towards representing hospitals, pharmacies, physician groups and other health care professionals and organizations in a variety of health care matters.

Joshua is a licensed pharmacist and is member of Polsinelli's pharmacy and 340B teams and assists with day-to-day regulatory, audit and transactional matters. He received his Pharm.D. from the University of Oklahoma College of Pharmacy. Prior to earning his law degree, Joshua practiced as a pharmacist in a variety of settings. He has extensive experience in pharmacy compounding and the various regulatory and legal issues facing pharmacy clients. Joshua uses his hands-on experience and understanding to advise a broad set of health care entities.

## Education

- University of Tulsa College of Law (J.D., 2021)
- Northeastern State University (B.G.S., *summa cum laude*)
- University of Oklahoma College of Pharmacy (Pharm.D.)

## Bar Admissions

- Kansas, 2026
- Missouri, 2021

## Memberships

- American Health Lawyers Association (AHLA)
- American Society for Pharmacy Law (ASPL)

## Recognition

- Adjunct professor at University of Kansas School of Pharmacy
  - Co-teaching course on pharmacy law

## Capabilities

- 340B Drug Pricing Program
- Health Care
- Hospitals & Health Systems
- Pharmacy
- Licensure, Enrollment & Certification
- Home Health, Home Care & Hospice

- Named one of *Best Lawyers: Ones to Watch®* in America in Health Care Law, 2025-2026

## Publications

---

April 28, 2026

**Not Just a Form: Eleventh Circuit Upholds CMS-855 Conviction, Expanding Medicare Enrollment Risk**

April 22, 2026

**Tiny Chains, Big Changes? What FDA's Latest Actions Mean for Peptide Compounding**

April 7, 2026

**Not Joking Around: FDA Offers Additional Clarification on Compounded GLP-1 Policy in April Fool's Day Announcement**

April 2, 2026

**NYBOP May 2026 Deadline Is Fast Approaching: Do Your Pharmacy and Pharmacists Have the Right Licenses?**

February 9, 2026

**FDA Tightens the Belt on GLP-1 Compounding, Escalating Threat of Enforcement**

January 20, 2026

**2026 Health Care Reimbursement Newsletter**

December 31, 2025

**Illinois Extends Compliance Deadline for Non-Resident PICs to March 30, 2026**

November 11, 2025

**Connecticut DSS Home Care Provider Registry: Employer Reporting Started October 1, 2025**

July 10, 2025

**Needle Little Regulation: What Texas's New IV Therapy Law Really Says**

February 2025

**2025 Health Care Reimbursement Newsletter**

December 12, 2024

**Massachusetts Issues Additional Update to Non-Resident Pharmacy Rules**

November 21, 2024

**Santa is Bringing Long-Awaited Regulatory Changes to Massachusetts Pharmacy Licensure**

January 4, 2024

**Reimbursement End-of-Year Highlights**

December 18, 2023

**Medicare Continues its Updates to Provider Enrollment Policies as Part of Efforts to Enhance Program Integrity and Transparency**

October 12, 2023

**DEA Issues Second Temporary Rule Extending Controlled Substance Prescribing Flexibilities Through December 2024**

March 1, 2023

**Health Care Reimbursement and Payor Dispute Update**